drugset / Press release
Artery is pleased to inform that the Drug Safety and Monitoring Board today concluded that CS6253 was safe and showed favorable pharmacokinetics in the Phase 1 Single Ascending Dose study (n=40), and recommended the transition to the Phase 1 Multiple Ascending Dose Study (NCT05965414).
2024-04-05 · Artery Therapeutics, Inc. · original arterytx.com ↗
Artery is pleased to inform that the Drug Safety and Monitoring Board today concluded that CS6253 was safe and showed favorable pharmacokinetics in the Phase 1 Single Ascending Dose study (n=40), and recommended the transition to the Phase 1 Multiple Ascending Dose Study (NCT05965414).
The release as fetched from its publisher. arterytx.com ↗